CSIMarket
 


Organovo Holdings Inc   (ONVO)
Other Ticker:  
 

Cumulative Organovo Holdings Inc 's Working Capital Ratio for Trailing Twelve Months Period

ONVO's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ONVO Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
Y / Y Current Liabilities Growth 15.19 % 38.07 % 165.44 % -31.41 % -17.07 %
Y / Y Current Assets Growth -65.94 % -56.54 % -42.27 % -30.66 % -28.99 %
Working Capital Ratio for Trailing Twelve Months Period 6.97 9.1 11.65 18.86 18.48
Total Ranking # 458 # 348 # 281 # 141 # 175
Seq. Current Liabilities Growth -9.6 % -51.78 % 166.79 % -0.94 % 8.35 %
Seq. Current Assets Growth -29.06 % -31.4 % -21.13 % -11.26 % -9.48 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to decrease in Current Liabilities in the II. Quarter to $2 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 6.97 below Organovo Holdings Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 89 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Organovo Holdings Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ONVO
Working Capital Ratio ONVO in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 90
Sector # 406
S&P 500 # 655


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
36.14 16 6.97
(Jun 30 2021)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Cabaletta Bio Inc   18.07 
Neumora Therapeutics Inc   18.05 
4d Molecular Therapeutics Inc   17.96 
Tourmaline Bio Inc   17.78 
Icosavax Inc   17.13 
Krystal Biotech Inc   17.05 
Replimune Group Inc   16.89 
Fusion Pharmaceuticals Inc   16.57 
Protara Therapeutics Inc   16.40 
Apogee Therapeutics inc   16.01 
Revolution Medicines Inc   15.83 
Aura Biosciences Inc   15.74 
Relay Therapeutics Inc   14.85 
Compass Therapeutics Inc   14.79 
Creative Medical Technology Holdings Inc   14.75 
Crispr Therapeutics Ag  14.35 
Achilles Therapeutics Plc  14.24 
Molecular Partners Ag  14.12 
Anavex Life Sciences Corp   13.98 
Kymera Therapeutics Inc   13.88 
Voyager Therapeutics Inc   13.37 
Tarsus Pharmaceuticals Inc   13.32 
Rubius Therapeutics Inc   13.17 
Cardiff Oncology inc   12.95 
Ikena Oncology Inc   11.97 
Aim Immunotech Inc   11.63 
Springworks Therapeutics Inc   11.28 
Scholar Rock Holding Corp  11.01 
Monte Rosa Therapeutics Inc   10.80 
Organovo Holdings Inc   10.75 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com